-
Je něco špatně v tomto záznamu ?
How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton
MC. Arendrup, G. Kahlmeter, J. Guinea, J. Meletiadis, Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)
Status minimální Jazyk angličtina
Typ dokumentu časopisecké články, přehledy
Grantová podpora
NV17-31269A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 1997 do Před 2 roky
Elsevier Open Access Journals
od 1996-03-01 do Před 1 rokem
Elsevier Open Archive Journals
od 1995 do Před 1 rokem
- MeSH
- antifungální látky farmakologie MeSH
- Arthrodermataceae účinky léků MeSH
- fungální léková rezistence účinky léků MeSH
- lidé MeSH
- mikrobiální testy citlivosti normy MeSH
- Trichophyton účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
BACKGROUND: Antifungal drug resistance in dermatophytes was first reported shortly after the turn of the millennium and has today been reported in Trichophyton and occasionally in Microsporum, but not in Epidermophyton species. Although drug resistance in dermatophytes is not routinely investigated, resistance in Trichophyton spp. is increasingly reported worldwide. The highest rates are observed in India (36% and 68% for terbinafine (MIC ≥4 mg/L) and fluconazole (MICs ≥16 mg/L), respectively), and apparently involve the spread of a unique clade related to the Trichophyton mentagrophytes/Trichophyton interdigitale complex. OBJECTIVES: The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has released a new method (E.Def 11.0) for antifungal susceptibility testing against microconidia-forming dermatophytes including tentative MIC ranges for quality control strains and tentative breakpoints against Trichophyton rubrum and T. interdigitale. Here, the details of the new procedure E.Def 11.0 are described. SOURCES: This technical note is based on the multicentre validation of the EUCAST dermatophyte antifungal susceptibility testing method, the mould testing method (E.Def 9.3.2) and the updated quality control tables for antifungal susceptibility testing document, v 5.0 (available on the EUCAST website). CONTENTS: The method is based on the EUCAST microdilution method for moulds but significant differences include: (a) an altered test medium selective for dermatophytes; (b) an altered incubation time and temperature; and (c) a different end-point criterion (spectrophotometric determination) of fungal growth. It can easily be implemented in laboratories already performing EUCAST microdilution methods and has been validated for terbinafine, voriconazole, itraconazole and amorolfine against T. rubrum and T. interdigitale. IMPLICATIONS: This standardized procedure with automated end-point reading will allow broader implementation of susceptibility testing of dermatophytes and so facilitate earlier appropriate therapy. This is important, as resistance is rapidly emerging and largely underdiagnosed.
CIBER de Enfermedades Respiratorias CIBERES Madrid Spain
Department of Clinical Medicine University of Copenhagen Denmark
Department of Clinical Microbiology University Hospital Rigshospitalet Copenhagen Denmark
Department of Medical Microbiology and Infectious Diseases Erasmus MC Rotterdam the Netherlands
Instituto de Investigación Sanitaria Gregorio Marañón Madrid Spain
The EUCAST Development Laboratory Clinical Microbiology Växjö Sweden
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22008623
- 003
- CZ-PrNML
- 005
- 20221031125232.0
- 007
- ta
- 008
- 220329s2021 Eng f 000 0|0 0|e
- 009
- AR
- 024 7_
- $a 10.1016/j.cmi.2020.08.042 $2 doi
- 035 __
- $a (PubMed)32916260
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a England
- 100 1_
- $a Arendrup, Maiken C $u Unit of Mycology, Department of Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark; Department of Clinical Microbiology, University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark. Electronic address: maca@ssi.dk
- 245 10
- $a How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton / $c MC. Arendrup, G. Kahlmeter, J. Guinea, J. Meletiadis, Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)
- 520 9_
- $a BACKGROUND: Antifungal drug resistance in dermatophytes was first reported shortly after the turn of the millennium and has today been reported in Trichophyton and occasionally in Microsporum, but not in Epidermophyton species. Although drug resistance in dermatophytes is not routinely investigated, resistance in Trichophyton spp. is increasingly reported worldwide. The highest rates are observed in India (36% and 68% for terbinafine (MIC ≥4 mg/L) and fluconazole (MICs ≥16 mg/L), respectively), and apparently involve the spread of a unique clade related to the Trichophyton mentagrophytes/Trichophyton interdigitale complex. OBJECTIVES: The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has released a new method (E.Def 11.0) for antifungal susceptibility testing against microconidia-forming dermatophytes including tentative MIC ranges for quality control strains and tentative breakpoints against Trichophyton rubrum and T. interdigitale. Here, the details of the new procedure E.Def 11.0 are described. SOURCES: This technical note is based on the multicentre validation of the EUCAST dermatophyte antifungal susceptibility testing method, the mould testing method (E.Def 9.3.2) and the updated quality control tables for antifungal susceptibility testing document, v 5.0 (available on the EUCAST website). CONTENTS: The method is based on the EUCAST microdilution method for moulds but significant differences include: (a) an altered test medium selective for dermatophytes; (b) an altered incubation time and temperature; and (c) a different end-point criterion (spectrophotometric determination) of fungal growth. It can easily be implemented in laboratories already performing EUCAST microdilution methods and has been validated for terbinafine, voriconazole, itraconazole and amorolfine against T. rubrum and T. interdigitale. IMPLICATIONS: This standardized procedure with automated end-point reading will allow broader implementation of susceptibility testing of dermatophytes and so facilitate earlier appropriate therapy. This is important, as resistance is rapidly emerging and largely underdiagnosed.
- 650 _2
- $a antifungální látky $x farmakologie $7 D000935
- 650 _2
- $a Arthrodermataceae $x účinky léků $7 D003883
- 650 _2
- $a fungální léková rezistence $x účinky léků $7 D025141
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikrobiální testy citlivosti $x normy $7 D008826
- 650 _2
- $a Trichophyton $x účinky léků $7 D014249
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kahlmeter, Gunnar $u The EUCAST Development Laboratory, Clinical Microbiology, Växjö, Sweden
- 700 1_
- $a Guinea, Jesus $u Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- 700 1_
- $a Meletiadis, Joseph $u Clinical Microbiology Laboratory, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands
- 710 2_
- $a Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)
- 773 0_
- $w MED00001139 $t Clinical microbiology and infection $x 1198-743X $g Roč. 27, č. 1 (2021), s. 55-60
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32916260 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220329 $b ABA008
- 991 __
- $a 20221031125230 $b ABA008
- 999 __
- $a min $b bmc $g 1775521 $s 1159817
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 27 $c 1 $d 55-60 $e 20200908 $i 1198-743X $m Clinical microbiology and infection $n Clin Microbiol Infect $x MED00001139
- GRA __
- $a NV17-31269A $p MZ0
- LZP __
- $a Pubmed-20220329